
Trainee Analyst - Commercial Analytics & Forecasting (BMS International account)
PharmaACE · Jun 2026 – Present
- Built patient-based revenue forecasting models for Bristol Myers Squibb oncology and haematology brands (Opdualag, Reblozyl) across US and Latin American markets; the US Opdualag model reproduced FY2023-25 net revenue to within 2% variance.
- Designed a reusable single-sheet country model template standardising epidemiology inputs, segment splits and conversion parameters, cutting setup time for each new market build.
- Built and automated a Power BI reporting suite with monthly, quarterly and annual views on a rolling 12-month window, refreshing directly from a single Excel input with no manual rework; adopted by the team for client reporting.
- Reconciled Mexican government procurement data (gob360) against IQVIA for five molecules, flagging records where processed units exceeded maximum permitted units and escalating the data-integrity issue to the client.
- Authored competitive-intelligence dossiers on OPDIVO, Yervoy, Opdualag, Reblozyl and BMS CELMOD assets (ZENBEXUS, mezigdomide), covering pipeline stage, patent position and biosimilar entry timing.
- Assessed biosimilar impact in oncology across Mexico, Colombia and Peru via analogue analysis, and evaluated the commercial case for a subcutaneous formulation switch.
- Estimated classical Hodgkin lymphoma incidence for Colombia by trending DRG epidemiology data from seven reference markets; modelled the effect of the SWOG S1826 readout on the Colombian forecast.


